QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
While we are all waiting for the delayed implementing acts for the EU HTA and the Joint Clinical Assessment (JCA), let´s summarize what we know so far about JCA
· What is it?
JCA is a streamlined EU-level process that evaluates the relative effectiveness and safety of new treatments compared to a range of alternative treatments. It considers a range of relevant treatments across EU member states. The resulting JCA report informs national HTA processes.
· Aim:
The JCA aims to eliminate inequality across European countries, reduce redundancy in the parallel national HTA processes, increase quality of […]
Welcome Ana!
Quantify is proud to introduce Ana Buzatu, who will support our Model, Access, and Strategy team in Stockholm as a Junior Research Analyst.
Ana is a pharmacist currently pursuing a master’s degree in Health economics, Policy and Management at Karolinska Institutet. Before joining Quantify, she worked in the pharmaceutical and diagnostics industry, bringing an integrated perspective on access and policy.
“I am excited to be part of […]
How can global pharma harness the power of Scandinavian RWE?
Make sure you’ve read Quantify’s CEO Kirk Geale‘s PharmaTimes article published late last year, explaining how global pharmaceutical executives can harness the power of Scandinavian health data to achieve regulatory and commercial success.
As the leading provider of Nordic RWE, Quantify can help you plan and execute your global RWE strategy using some of the world’s best data. Get in […]
The potential of health data is the main agenda topic at this year´s Norway Life Science Conference in Oslo
BCG has prepared a report pointing to five main areas for improvement in the Norwegian real-world data landscape:
1. Performing holistic mapping of the process of accessing health data to identify bottlenecks and inform future priorities for progress
2. Clarifying and adapting the regulatory framework
3. Promoting international and public-private collaboration
4. Strengthening and building on existing infrastructure
5. Developing actionable KPIs to track progress
Quantify have a long and solid experience in applying for, extracting, […]